Biodesix announced Scott Hutton will become the firm's CEO, effective Jan. 1, 2020. Current CEO David Brunel will become the chairman and will continue in a day-to-day advisory capacity assisting with strategic direction and key partnerships, the company said. He is a cofounder of Biodesix and has led the firm for more than 13 years.
Hutton is currently Biodesix's COO and has more than 20 years of experience in the medical device, medical technology, and diagnostics industries. Prior to joining Biodesix, he was senior vice president and general manager of vascular interventions at Spectranetics, and VP, GM of neurosurgery at Medtronic.